Terms: = Breast cancer AND ARNT, HIF1BETA, 405, ENSG00000143437, P27540, HIF-1beta, HIF1B, TANGO AND Prognosis
30 results:
1. The relationship of changes in molecular subtypes with metastases and progression-free survival in breast cancer.
Amansyah F; Prihantono P; Hamid F; Syamsu SA; Pieter J; Faruk M
Breast Dis; 2024; 43(1):71-78. PubMed ID: 38669518
[TBL] [Abstract] [Full Text] [Related]
2. "Time" for obesity-related cancer: The role of the circadian rhythm in cancer pathogenesis and treatment.
Miro C; Docimo A; Barrea L; Verde L; Cernea S; Sojat AS; Marina LV; Docimo G; Colao A; Dentice M; Muscogiuri G
Semin Cancer Biol; 2023 Jun; 91():99-109. PubMed ID: 36893964
[TBL] [Abstract] [Full Text] [Related]
3. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Tolaney SM; Tarantino P; Graham N; Tayob N; Parè L; Villacampa G; Dang CT; Yardley DA; Moy B; Marcom PK; Albain KS; Rugo HS; Ellis MJ; Shapira I; Wolff AC; Carey LA; Barroso-Sousa R; Villagrasa P; DeMeo M; DiLullo M; Zanudo JGT; Weiss J; Wagle N; Partridge AH; Waks AG; Hudis CA; Krop IE; Burstein HJ; Prat A; Winer EP
Lancet Oncol; 2023 Mar; 24(3):273-285. PubMed ID: 36858723
[TBL] [Abstract] [Full Text] [Related]
4. Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy
Denkert C; Untch M; Benz S; Schneeweiss A; Weber KE; Schmatloch S; Jackisch C; Sinn HP; Golovato J; Karn T; Marmé F; Link T; Budczies J; Nekljudova V; Schmitt WD; Stickeler E; Müller V; Jank P; Parulkar R; Heinmöller E; Sanborn JZ; Schem C; Sinn BV; Soon-Shiong P; van Mackelenbergh M; Fasching PA; Rabizadeh S; Loibl S
Ann Oncol; 2021 Apr; 32(4):500-511. PubMed ID: 33418062
[TBL] [Abstract] [Full Text] [Related]
5. Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative breast cancer in the Randomized TAILORx Trial.
Albain KS; Gray RJ; Makower DF; Faghih A; Hayes DF; Geyer CE; Dees EC; Goetz MP; Olson JA; Lively T; Badve SS; Saphner TJ; Wagner LI; Whelan TJ; Ellis MJ; Wood WC; Keane MM; Gomez HL; Reddy PS; Goggins TF; Mayer IA; Brufsky AM; Toppmeyer DL; Kaklamani VG; Berenberg JL; Abrams J; Sledge GW; Sparano JA
J Natl Cancer Inst; 2021 Apr; 113(4):390-399. PubMed ID: 32986828
[TBL] [Abstract] [Full Text] [Related]
6. Compliance with multidisciplinary team recommendations and disease outcomes in early breast cancer patients: An analysis of 4501 consecutive patients.
Yang X; Huang J; Zhu X; Shen K; Zhu J; Chen X
Breast; 2020 Aug; 52():135-145. PubMed ID: 32512360
[TBL] [Abstract] [Full Text] [Related]
7. Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy.
Liao Y; Liao Y; Li J; Xiong J; Fan Y
Sci Rep; 2020 Apr; 10(1):7349. PubMed ID: 32355298
[TBL] [Abstract] [Full Text] [Related]
8. Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer.
Fernandez-Garcia D; Hills A; Page K; Hastings RK; Toghill B; Goddard KS; Ion C; Ogle O; Boydell AR; Gleason K; Rutherford M; Lim A; Guttery DS; Coombes RC; Shaw JA
Breast Cancer Res; 2019 Dec; 21(1):149. PubMed ID: 31856868
[TBL] [Abstract] [Full Text] [Related]
9. Gender Disparity in Referral for Definitive Care of Malignant Pleural Effusions.
Foote DC; Burke CR; Pandian B; Banks S; Haug KL; Hipp M; Zhao L; Smola B; Roh M; Carrott PW; Lynch WR; Chang AC; Lin J; Reddy RM
J Surg Res; 2019 Dec; 244():409-416. PubMed ID: 31325663
[TBL] [Abstract] [Full Text] [Related]
10. Integrated network analysis and machine learning approach for the identification of key genes of triple-negative breast cancer.
Naorem LD; Muthaiyan M; Venkatesan A
J Cell Biochem; 2019 Apr; 120(4):6154-6167. PubMed ID: 30302816
[TBL] [Abstract] [Full Text] [Related]
11. Factors associated with long-term survival in central nervous system metastases.
Cacho-Díaz B; Spínola-Maroño H; González-Aguilar A; Arrieta O
J Neurooncol; 2018 Oct; 140(1):159-164. PubMed ID: 30003395
[TBL] [Abstract] [Full Text] [Related]
12. Overexpression of arnt2 is associated with decreased cell proliferation and better prognosis in gastric cancer.
Jia Y; Hao S; Jin G; Li H; Ma X; Zheng Y; Xiao D; Wang Y
Mol Cell Biochem; 2019 Jan; 450(1-2):97-103. PubMed ID: 29948506
[TBL] [Abstract] [Full Text] [Related]
13. Transforming growth factor beta 1 (TGFβ1) polymorphisms and haplotype structures have dual roles in breast cancer pathogenesis.
Vitiello GAF; Guembarovski RL; Hirata BKB; Amarante MK; de Oliveira CEC; de Oliveira KB; Cebinelli GCM; Guembarovski AL; Campos CZ; Watanabe MAE
J Cancer Res Clin Oncol; 2018 Apr; 144(4):645-655. PubMed ID: 29362917
[TBL] [Abstract] [Full Text] [Related]
14. Identifying accessible prognostic factors for breast cancer relapse: a case-study on 405 histologically confirmed node-negative patients.
Zemni I; Ghalleb M; Jbir I; Slimane M; Ben Hassouna J; Ben Dhieb T; Bouzaiene H; Rahal K
World J Surg Oncol; 2017 Nov; 15(1):206. PubMed ID: 29169398
[TBL] [Abstract] [Full Text] [Related]
15. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage breast cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?
Jasem J; Fisher CM; Amini A; Shagisultanova E; Rabinovitch R; Borges VF; Elias A; Kabos P
J Natl Compr Canc Netw; 2017 Apr; 15(4):494-503. PubMed ID: 28404760
[No Abstract] [Full Text] [Related]
16. [Surgical treatment and prognosis of ductal carcinoma in situ: 526 cases analysis].
Zhu SJ; Chen XS; Wu JY; Huang O; He JR; Zhu L; Chen WG; Li YF; Fei XC; Shen KW
Zhonghua Wai Ke Za Zhi; 2017 Feb; 55(2):114-119. PubMed ID: 28162210
[No Abstract] [Full Text] [Related]
17. HRG/HER2/HER3 signaling promotes AhR-mediated Memo-1 expression and migration in colorectal cancer.
Bogoevska V; Wolters-Eisfeld G; Hofmann BT; El Gammal AT; Mercanoglu B; Gebauer F; Vashist YK; Bogoevski D; Perez D; Gagliani N; Izbicki JR; Bockhorn M; Güngör C
Oncogene; 2017 Apr; 36(17):2394-2404. PubMed ID: 27941874
[TBL] [Abstract] [Full Text] [Related]
18. FOXK2 Elicits Massive Transcription Repression and Suppresses the Hypoxic Response and breast cancer Carcinogenesis.
Shan L; Zhou X; Liu X; Wang Y; Su D; Hou Y; Yu N; Yang C; Liu B; Gao J; Duan Y; Yang J; Li W; Liang J; Sun L; Chen K; Xuan C; Shi L; Wang Y; Shang Y
Cancer Cell; 2016 Nov; 30(5):708-722. PubMed ID: 27773593
[TBL] [Abstract] [Full Text] [Related]
19. Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer.
Carbognin L; Sperduti I; Brunelli M; Marcolini L; Nortilli R; Pilotto S; Zampiva I; Merler S; Fiorio E; Filippi E; Manfrin E; Pellini F; Bonetti F; Pollini GP; Tortora G; Bria E
J Exp Clin Cancer Res; 2016 Mar; 35():50. PubMed ID: 27000271
[TBL] [Abstract] [Full Text] [Related]
20. A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities.
Abraham JE; Hiller L; Dorling L; Vallier AL; Dunn J; Bowden S; Ingle S; Jones L; Hardy R; Twelves C; Poole CJ; Pharoah PD; Caldas C; Earl HM
BMC Med; 2015 Dec; 13():306. PubMed ID: 26715442
[TBL] [Abstract] [Full Text] [Related]
[Next]
